admin – Page 8109 – Get News Story

Latest Updates on Myopia Pipeline Analysis in 2023: Recent FDA, EMA, and PMDA Approvals Explored by Pfizer, ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica, and Johnson & Johnson

“Myopia Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myopia pipeline constitutes 10+ key companies continuously working towards developing 12+ Myopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Myopia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Myopia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myopia Market.

Some of the key takeaways from the Myopia Pipeline Report:

Companies across the globe are diligently working toward developing novel Myopia treatment therapies with a considerable amount of success over the years.
Myopia companies working in the treatment market are Santen Pharmaceutical, Sunhawk Vision Biotech, Nevakar, Inc., Cloudbreak Therapeutics, LLC, iVeena Delivery Systems, Sydnexis, Inc., Nevakar, Inc., and others, are developing therapies for the Myopia treatment

Emerging Myopia therapies in the different phases of clinical trials are- STN-1013400, SHJ002, EXP039, CBT-009, IVMED 85, DE 127, SYD-101, NVK-002, and others are expected to have a significant impact on the Myopia market in the coming years.
In October 2023, The PROTECT clinical trial for Visioneering Technologies Inc.’s (VTI) NaturalVue Multifocal 1 Day paediatric myopia progression control contact lenses produced positive interim one-year findings. The findings, which were presented at the American Academy of Optometry Annual Meeting in October 2023, validate the NaturalVue Multifocal 1 Day contact lenses’ effectiveness and safety in slowing the advancement of myopia.
In October 2021, The Food and Drug Administration approved Allergan, an AbbVie subsidiary, to market Vuity (pilocarpine hydrochloric acid ophthalmic solution) 1.25% to treat presbyopia, or age-related hazy near vision, in adults.
In May 2021, The US FDA approved Johnson & Johnson Vision’s ACUVUE Abiliti Overnight Therapeutic Lenses, which are intended to help correct children’s progressive myopia by reshaping the cornea.

Myopia Overview

The most prevalent type of Refractive Error (RE), known as myopia or shortsightedness, causes a person to have clear near vision but poor distance vision. In this case, near refers to the reading distance of 35–40 cm, and far denotes more than three feet. “Rays of light coming from infinity cannot focus in the retina, instead it is focused in front of the retina, when accommodation function is at rest,” is the clinical definition of myopia.

Get a Free Sample PDF Report to know more about Myopia Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/myopia-pipeline-insight

Emerging Myopia Drugs Under Different Phases of Clinical Development Include:

STN-1013400: Santen Pharmaceutical
SHJ002: Sunhawk Vision Biotech
EXP039: Nevakar, Inc.
CBT-009: Cloudbreak Therapeutics, LLC
IVMED 85: iVeena Delivery Systems
DE 127: Santen Pharmaceutical
SYD-101: Sydnexis, Inc.
NVK-002: Nevakar, Inc.

Myopia Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Myopia Molecule Type

Myopia Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Myopia Pipeline Therapeutics Assessment

Myopia Assessment by Product Type
Myopia By Stage and Product Type
Myopia Assessment by Route of Administration
Myopia By Stage and Route of Administration
Myopia Assessment by Molecule Type
Myopia by Stage and Molecule Type

DelveInsight’s Myopia Report covers around 12+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Myopia product details are provided in the report. Download the Myopia pipeline report to learn more about the emerging Myopia therapies

Some of the key companies in the Myopia Therapeutics Market include:

Key companies developing therapies for Myopia are – ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica (Essilor Ltd), Johnson & Johnson Vision, NIDEK CO. LTD, Topcon Corporation, Zeimer Ophthalmic Systems AG, Carl Zeiss Meditec AG, AbbVie, Sydnexis, Regeneron Pharmaceuticals Inc., Orasis Pharmaceuticals, The Cooper Companies Inc., and others.

Myopia Pipeline Analysis:

The Myopia pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Myopia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia Treatment.
Myopia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Myopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myopia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myopia drugs and therapies

Myopia Pipeline Market Drivers

Increase in the prevalence of Myopia, increasing Research and Development activities are some of the important factors that are fueling the Myopia Market.

Myopia Pipeline Market Barriers

However, cost associated with the treatment, unclear pathogenesis of the disease and other factors are creating obstacles in the Myopia Market growth.

Scope of Myopia Pipeline Drug Insight

Coverage: Global
Key Myopia Companies: Santen Pharmaceutical, Sunhawk Vision Biotech, Nevakar, Inc., Cloudbreak Therapeutics, LLC, iVeena Delivery Systems, Santen Pharmaceutical, Sydnexis, Inc., Nevakar, Inc., and others
Key Myopia Therapies: STN-1013400, SHJ002, EXP039, CBT-009, IVMED 85, DE 127, SYD-101, NVK-002, and others
Myopia Therapeutic Assessment: Myopia current marketed and Myopia emerging therapies
Myopia Market Dynamics: Myopia market drivers and Myopia market barriers

Request for Sample PDF Report for Myopia Pipeline Assessment and clinical trials

Table of Contents

1. Myopia Report Introduction

2. Myopia Executive Summary

3. Myopia Overview

4. Myopia- Analytical Perspective In-depth Commercial Assessment

5. Myopia Pipeline Therapeutics

6. Myopia Late Stage Products (Phase II/III)

7. Myopia Mid Stage Products (Phase II)

8. Myopia Early Stage Products (Phase I)

9. Myopia Preclinical Stage Products

10. Myopia Therapeutics Assessment

11. Myopia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myopia Key Companies

14. Myopia Key Products

15. Myopia Unmet Needs

16 . Myopia Market Drivers and Barriers

17. Myopia Future Perspectives and Conclusion

18. Myopia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Latest Updates on Myopia Pipeline Analysis in 2023: Recent FDA, EMA, and PMDA Approvals Explored by Pfizer, ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica, and Johnson & Johnson

Exploring the Landscape of Acute Kidney Injury Pipeline Drugs 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, & ROA Unveiled by DelveInsight | Atox Bio, AM Pharma Holding, QuarK

“Acute Kidney Injury Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Kidney Injury pipeline constitutes 30+ key companies continuously working towards developing 30+ Acute Kidney Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Kidney Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acute Kidney Injury Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Kidney Injury Market.

Some of the key takeaways from the Acute Kidney Injury Pipeline Report:

Companies across the globe are diligently working toward developing novel Acute Kidney Injury treatment therapies with a considerable amount of success over the years.
Acute Kidney Injury companies working in the treatment market are Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis, Angion Biomedica, Vifor Pharma, AM Pharma, Astellas Pharma, Pharming Technologies, RegeneRx Biopharmaceuticals, and others, are developing therapies for the Acute Kidney Injury treatment

Emerging Acute Kidney Injury therapies in the different phases of clinical trials are- REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, ANG-3777, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), Timbetasin, and others are expected to have a significant impact on the Acute Kidney Injury market in the coming years.
In October 2022, The FDA in the United States approved Guard Therapeutics’ application for an investigational new drug (IND) for RMC-035 (ROSgard), the firm reported.
In March 2022, A phase two randomised, placebo-controlled, double-blind, adaptive, parallel group clinical trial to assess the effectiveness and safety of RMC-035 in patients at high risk of acute kidney injury after open chest cardiac surgery was started by Guard Therapeutics AB.
In February 2022, Family offices that specialize in investing in biotech led Renibus Therapeutics‘ Series A financing round, which was closed at USD 35 million after the company completed a USD 15 million extension. Renibus’ pipeline, which includes RBT-1, one of the company’s main candidates for the prevention of acute kidney injury, will be advanced with the help of the funding proceeds.
In March 2022, An summary of the ongoing Phase III REVIVAL trial will be presented by AM-Pharma at the 27th International Conference on Advances in Critical Care Nephrology.

Acute Kidney Injury Overview

Acute kidney damage is characterized by a sudden decline in renal function that occurs within a few days to weeks. This can result in azotemia, or a buildup of nitrogenous products in the blood, with or without a drop in urine production.

Get a Free Sample PDF Report to know more about Acute Kidney Injury Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight

Emerging Acute Kidney Injury Drugs Under Different Phases of Clinical Development Include:

REVTx-300: Revelation Biosciences
RGN-352: RegeneRx Biopharmaceuticals
MTX652: MISSION Therapeutics
UNI-494: Unicycive Therapeutics
SBI-101: Sentien Biotechnologies
MIB-626: Metro International Biotech
RMC-035: Guard Therapeutics AB
TIN816: Novartis Pharmaceuticals
ANG-3777: Angion Biomedica/Vifor Pharma
Ilofotase alfa: AM Pharma
ASP1128: Astellas Pharma
Ruconest (Conestat alfa): Pharming Technologies
Timbetasin: RegeneRx Biopharmaceuticals

Acute Kidney Injury Route of Administration

Acute Kidney Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Acute Kidney Injury Molecule Type

Acute Kidney Injury Products have been categorized under various Molecule types, such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Acute Kidney Injury Pipeline Therapeutics Assessment

Acute Kidney Injury Assessment by Product Type
Acute Kidney Injury By Stage and Product Type
Acute Kidney Injury Assessment by Route of Administration
Acute Kidney Injury By Stage and Route of Administration
Acute Kidney Injury Assessment by Molecule Type
Acute Kidney Injury by Stage and Molecule Type

DelveInsight’s Acute Kidney Injury Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Acute Kidney Injury product details are provided in the report. Download the Acute Kidney Injury pipeline report to learn more about the emerging Acute Kidney Injury therapies

Some of the key companies in the Acute Kidney Injury Therapeutics Market include:

Key companies developing therapies for Acute Kidney Injury are – Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX and others.

Acute Kidney Injury Pipeline Analysis:

The Acute Kidney Injury pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.
Acute Kidney Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.

Download Sample PDF Report to know more about Acute Kidney Injury drugs and therapies

Acute Kidney Injury Pipeline Market Drivers

Rising incidence of Acute Kidney injuries, the rising geriatric population are some of the important factors that are fueling the Acute Kidney Injury Market.

Acute Kidney Injury Pipeline Market Barriers

However, side-effects associated with the treatment, lack of awareness and other factors are creating obstacles in the Acute Kidney Injury Market growth.

Scope of Acute Kidney Injury Pipeline Drug Insight

Coverage: Global
Key Acute Kidney Injury Companies: Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis, Angion Biomedica, Vifor Pharma, AM Pharma, Astellas Pharma, Pharming Technologies, RegeneRx Biopharmaceuticals, and others
Key Acute Kidney Injury Therapies: REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, ANG-3777, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), Timbetasin, and others
Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers

Request for Sample PDF Report for Acute Kidney Injury Pipeline Assessment and clinical trials

Table of Contents

1. Acute Kidney Injury Report Introduction

2. Acute Kidney Injury Executive Summary

3. Acute Kidney Injury Overview

4. Acute Kidney Injury- Analytical Perspective In-depth Commercial Assessment

5. Acute Kidney Injury Pipeline Therapeutics

6. Acute Kidney Injury Late Stage Products (Phase II/III)

7. Acute Kidney Injury Mid Stage Products (Phase II)

8. Acute Kidney Injury Early Stage Products (Phase I)

9. Acute Kidney Injury Preclinical Stage Products

10. Acute Kidney Injury Therapeutics Assessment

11. Acute Kidney Injury Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Kidney Injury Key Companies

14. Acute Kidney Injury Key Products

15. Acute Kidney Injury Unmet Needs

16 . Acute Kidney Injury Market Drivers and Barriers

17. Acute Kidney Injury Future Perspectives and Conclusion

18. Acute Kidney Injury Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exploring the Landscape of Acute Kidney Injury Pipeline Drugs 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, & ROA Unveiled by DelveInsight | Atox Bio, AM Pharma Holding, QuarK

Chronic Refractory Cough Pipeline Drugs Update (2023) – FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Administration Routes by DelveInsight | Focus on Genentech and Trevi

“Chronic Refractory Cough Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Refractory Cough pipeline constitutes key companies continuously working towards developing Chronic Refractory Cough treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Chronic Refractory Cough Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Refractory Cough Market.

The Chronic Refractory Cough Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Refractory Cough Pipeline Report:

Companies across the globe are diligently working toward developing novel Chronic Refractory Cough treatment therapies with a considerable amount of success over the years.
Chronic Refractory Cough companies working in the treatment market are Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others, are developing therapies for the Chronic Refractory Cough treatment

Emerging Chronic Refractory Cough therapies in the different phases of clinical trials are- NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others are expected to have a significant impact on the Chronic Refractory Cough market in the coming years.
In June 2023, Bellus Health Inc. and GSK plc declared Bellus has been fully acquired by GSK. Camlipixant, a potentially best-in-class and highly selective P2X3 antagonist that is presently in phase III development for the first-line treatment of adult patients with refractory chronic cough, is part of the Bellus purchase.
In January 2023, A Phase III, 24-week, randomized, double-blind, placebo-controlled, parallel-arm effectiveness and safety trial was started by Bellus Health Inc. with an open-label extension of BLU-5937 for adult participants with refractory chronic cough, including chronic cough that is not explained. The experiment is expected to conclude with 675 participants by July 2025.
In October 2022, A 52-week Phase III randomized, double-blind, placebo-controlled, parallel-arm effectiveness and safety trial was started by Bellus Health Inc. with an open-label extension of blu-5937 for adult participants with refractory chronic cough, including chronic cough without apparent cause.

Chronic Refractory Cough Overview

A cough that lasts longer than eight weeks is referred to as chronic, and many individuals with chronic refractory cough have coughs that last considerably longer. Furthermore, the illness is known as chronic refractory cough when the reason of the persistent cough cannot be found or the cough continues even after receiving the best care possible for any related conditions.

Get a Free Sample PDF Report to know more about Chronic Refractory Cough Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/chronic-refractory-cough-pipeline-insight

Emerging Chronic Refractory Cough Drugs Under Different Phases of Clinical Development Include:

NOC-100: Nocion Therapeutics
GDC-6599: Genentech, Inc.
Haduvio: Trevi Therapeutics
HRS-2261: Guangdong Hengrui Pharmaceutical Co., Ltd
BLU-5937: Bellus Health Inc
MK-7264 (gefapixant): Merck & Co/Kyorin Pharmaceuticals
Orvepitant Maleate: NeRRe Therapeutics
Camlipixant (BLU-5937): Bellus Health/GSK
AX-8: Axalbion
ADX-629: Aldeyra Therapeutics
GDC-6599: Genentech, Inc.

Chronic Refractory Cough Pipeline Therapeutics Assessment

Chronic Refractory Cough Assessment by Product Type
Chronic Refractory Cough By Stage and Product Type
Chronic Refractory Cough Assessment by Route of Administration
Chronic Refractory Cough By Stage and Route of Administration
Chronic Refractory Cough Assessment by Molecule Type
Chronic Refractory Cough by Stage and Molecule Type

DelveInsight’s Chronic Refractory Cough Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Chronic Refractory Cough product details are provided in the report. Download the Chronic Refractory Cough pipeline report to learn more about the emerging Chronic Refractory Cough therapies

Some of the key companies in the Chronic Refractory Cough Therapeutics Market include:

Key companies developing therapies for Chronic Refractory Cough are – Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, Shionogi, Axalbion, Aldeyra Therapeutics and others

Chronic Refractory Cough Pipeline Analysis:

The Chronic Refractory Cough pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Refractory Cough with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Refractory Cough Treatment.
Chronic Refractory Cough key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Refractory Cough Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Refractory Cough market.

Download Sample PDF Report to know more about Chronic Refractory Cough drugs and therapies

Chronic Refractory Cough Pipeline Market Drivers

Increasing Prevalence of cough, growing demand for treatment for Chronic Refractory Cough are some of the important factors that are fueling the Chronic Refractory Cough Market.

Chronic Refractory Cough Pipeline Market Barriers

However, lack of awareness, lack of availability of specific biomarkers that are useful for accurate and timely diagnosis and other factors are creating obstacles in the Chronic Refractory Cough Market growth.

Scope of Chronic Refractory Cough Pipeline Drug Insight

Coverage: Global
Key Chronic Refractory Cough Companies: Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others
Key Chronic Refractory Cough Therapies: NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others
Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies
Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers

Request for Sample PDF Report for Chronic Refractory Cough Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Refractory Cough Report Introduction

2. Chronic Refractory Cough Executive Summary

3. Chronic Refractory Cough Overview

4. Chronic Refractory Cough- Analytical Perspective In-depth Commercial Assessment

5. Chronic Refractory Cough Pipeline Therapeutics

6. Chronic Refractory Cough Late Stage Products (Phase II/III)

7. Chronic Refractory Cough Mid Stage Products (Phase II)

8. Chronic Refractory Cough Early Stage Products (Phase I)

9. Chronic Refractory Cough Preclinical Stage Products

10. Chronic Refractory Cough Therapeutics Assessment

11. Chronic Refractory Cough Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Refractory Cough Key Companies

14. Chronic Refractory Cough Key Products

15. Chronic Refractory Cough Unmet Needs

16 . Chronic Refractory Cough Market Drivers and Barriers

17. Chronic Refractory Cough Future Perspectives and Conclusion

18. Chronic Refractory Cough Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Refractory Cough Pipeline Drugs Update (2023) – FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Administration Routes by DelveInsight | Focus on Genentech and Trevi

Exploring Acute Myeloid Leukemia Pipeline and Clinical Trials 2023: FDA Approvals, Therapeutic Advances, Companies Analyzed by DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma

“Acute Myeloid Leukemia Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Myeloid Leukemia pipeline constitutes 260+ key companies continuously working towards developing 260+ Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acute Myeloid Leukemia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Myeloid Leukemia Market.

Some of the key takeaways from the Acute Myeloid Leukemia Pipeline Report:

Companies across the globe are diligently working toward developing novel Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years.
Acute Myeloid Leukemia companies working in the treatment market are SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, and others, are developing therapies for the Acute Myeloid Leukemia treatment

Emerging Acute Myeloid Leukemia therapies in the different phases of clinical trials are- GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, Fosciclopirox + Cytarabine, CPX351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, and others are expected to have a significant impact on the Acute Myeloid Leukemia market in the coming years.
In January 2023, Preclinical findings demonstrating the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123 was published in Nature Biotechnology, according to a statement from Innate Pharma SA.
In January 2023, According to a news statement from Jubilant Therapeutics, the FDA designated JBI-802 as an orphan medication for patients with acute myeloid leukemia (AML) and small cell lung cancer (SCLC).
In January 2022, Astex Pharmaceuticals, Inc. declared that the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the treatment of acute myeloid leukemia (AML) has been given orphan-drug designation (ODD) by the European Commission (EC).
In August 2022, Announcing that it will keep revising its estimate for the mid-2023 survival events trigger for its pivotal Phase 3 trial assessing uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML), GlycoMimetics said.

Acute Myeloid Leukemia Overview

About 80 percent of occurrences of leukemia in adults are acute myeloid leukemia (AML), making it the most prevalent kind in this population. The condition is typified by the clonal proliferation of immature “blast cells” in the bone marrow and peripheral circulation, leading to inefficient erythropoiesis and bone marrow failure.

Get a Free Sample PDF Report to know more about Acute Myeloid Leukemia Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight

Emerging Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:

GNC 035: SystImmune
JSP 191: Jasper Therapeutics
ONC201: Chimerix
AK117: Akeso Biopharma Co., Ltd.
Tamibarotene: Syros Pharmaceuticals
TCB008: TC Biopharm
Elzonris: Stemline Therapeutics
Orca T: Orca Bio
Magrolimab+ azacitidine: Gilead Sciences
Uproleselan: GlycoMimetics
Fosciclopirox + Cytarabine: CicloMed LLC
CPX351: Jazz Pharmaceuticals
Minnelide: Minneamrita Therapeutics LLC
SNDX-5613: Syndax Pharmaceuticals
ASTX727: Astex Pharmaceuticals, Inc.
KPT-9274: Karyopharm Therapeutics Inc
SAR445419: Sanofi

Acute Myeloid Leukemia Route of Administration

Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Intravenous
Subcutaneous

Acute Myeloid Leukemia Molecule Type

Acute Myeloid Leukemia Products have been categorized under various Molecule types, such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Acute Myeloid Leukemia Pipeline Therapeutics Assessment

Acute Myeloid Leukemia Assessment by Product Type
Acute Myeloid Leukemia By Stage and Product Type
Acute Myeloid Leukemia Assessment by Route of Administration
Acute Myeloid Leukemia By Stage and Route of Administration
Acute Myeloid Leukemia Assessment by Molecule Type
Acute Myeloid Leukemia by Stage and Molecule Type

DelveInsight’s Acute Myeloid Leukemia Report covers around 260+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Acute Myeloid Leukemia product details are provided in the report. Download the Acute Myeloid Leukemia pipeline report to learn more about the emerging Acute Myeloid Leukemia therapies

Some of the key companies in the Acute Myeloid Leukemia Therapeutics Market include:

Key companies developing therapies for Acute Myeloid Leukemia are – CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, Polaris Group, Bio-Path Holdings, Inc., Chordia Therapeutics, Inc., Theradex, BioTheryX, Inc., Precigen, Inc, Eli Lilly and Company, Bayer, Takeda, Meryx, Inc., 2seventy bio, JW Pharmaceutical, Telios Pharma, and others.

Acute Myeloid Leukemia Pipeline Analysis:

The Acute Myeloid Leukemia pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment.
Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market.

Download Sample PDF Report to know more about Acute Myeloid Leukemia drugs and therapies

Acute Myeloid Leukemia Pipeline Market Drivers

Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Acute Myeloid Leukemia Market.

Acute Myeloid Leukemia Pipeline Market Barriers

However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Acute Myeloid Leukemia Market growth.

Scope of Acute Myeloid Leukemia Pipeline Drug Insight

Coverage: Global
Key Acute Myeloid Leukemia Companies: SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, and others
Key Acute Myeloid Leukemia Therapies: GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, Fosciclopirox + Cytarabine, CPX351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, and others
Acute Myeloid Leukemia Therapeutic Assessment: Acute Myeloid Leukemia current marketed and Acute Myeloid Leukemia emerging therapies
Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia market drivers and Acute Myeloid Leukemia market barriers

Request for Sample PDF Report for Acute Myeloid Leukemia Pipeline Assessment and clinical trials

Table of Contents

1. Acute Myeloid Leukemia Report Introduction

2. Acute Myeloid Leukemia Executive Summary

3. Acute Myeloid Leukemia Overview

4. Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment

5. Acute Myeloid Leukemia Pipeline Therapeutics

6. Acute Myeloid Leukemia Late Stage Products (Phase II/III)

7. Acute Myeloid Leukemia Mid Stage Products (Phase II)

8. Acute Myeloid Leukemia Early Stage Products (Phase I)

9. Acute Myeloid Leukemia Preclinical Stage Products

10. Acute Myeloid Leukemia Therapeutics Assessment

11. Acute Myeloid Leukemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Myeloid Leukemia Key Companies

14. Acute Myeloid Leukemia Key Products

15. Acute Myeloid Leukemia Unmet Needs

16 . Acute Myeloid Leukemia Market Drivers and Barriers

17. Acute Myeloid Leukemia Future Perspectives and Conclusion

18. Acute Myeloid Leukemia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exploring Acute Myeloid Leukemia Pipeline and Clinical Trials 2023: FDA Approvals, Therapeutic Advances, Companies Analyzed by DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma

Pancreatic Ductal Adenocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Alligator Bioscience, Cardiff Oncology, Novartis, and others.

DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the Pancreatic Ductal Adenocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Ductal Adenocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

DelveInsight’s Pancreatic Ductal Adenocarcinoma Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma.
The leading companies working in the Pancreatic Ductal Adenocarcinoma Market include Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others are evaluating new drugs for pancreatic ductal adenocarcinoma to improve the treatment landscape.
Promising Pancreatic Ductal Adenocarcinoma Pipeline therapies include Mitazalimab, Onvansertib, NIS793, KN046, CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.
December 2023: Genentech Inc. announced a study of Phase 2 clinical trials for Autogene cevumeran and Atezolizumab. The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
December 2023: Georgetown University announced a study of Phase 2 clinical trials for Daratumumab and KRAS Vaccine. The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC).
November 2023: Agenus Inc. announced a study of Phase 2 clinical trials for Botensilimab and Gemcitabine. The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.

Request a sample and discover the recent advances in Pancreatic Ductal Adenocarcinoma Treatment Drugs @ Pancreatic Ductal Adenocarcinoma Pipeline Report

In the Pancreatic Ductal Adenocarcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Ductal Adenocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature.

Find out more about Pancreatic Ductal Adenocarcinoma Treatment Landscape @ Drugs for Pancreatic Ductal Adenocarcinoma Treatment

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

Onvansertib: Cardiff Oncology
Nadunolimab: Cantargia
Zimberelimab: Arcus Biosciences

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies Pancreatic Ductal Adenocarcinoma. The Pancreatic Ductal Adenocarcinoma companies which have their Pancreatic Ductal Adenocarcinoma drug candidates in the most advanced stage, i.e phase III include XOMA.

DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Learn more about the emerging Pancreatic Ductal Adenocarcinoma Pipeline Therapies @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report

Coverage- Global
Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Pancreatic Ductal Adenocarcinoma Companies- Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.
Pancreatic Ductal Adenocarcinoma Pipeline Therapies- Mitazalimab, Onvansertib, NIS793, KN046, CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.

Dive deep into rich insights for new drugs for Pancreatic Ductal Adenocarcinoma treatment, Visit @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Pancreatic Ductal Adenocarcinoma Executive Summary
Pancreatic Ductal Adenocarcinoma: Overview
Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
Pancreatic Ductal Adenocarcinoma Therapeutic Assessment
Pancreatic Ductal Adenocarcinoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
NIS 793: XOMA
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CEND 1: Cend Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
DCC-3116: Deciphera Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
RMC-6236: REVOLUTION Medicines
Drug profiles in the detailed report…..
Inactive Products
Pancreatic Ductal Adenocarcinoma Key Companies
Pancreatic Ductal Adenocarcinoma Key Products
Pancreatic Ductal Adenocarcinoma- Unmet Needs
Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
Pancreatic Ductal Adenocarcinoma Analyst Views
Pancreatic Ductal Adenocarcinoma Key Companies
Appendix

For further information on the Pancreatic Ductal Adenocarcinoma pipeline therapeutics, reach out @ Pancreatic Ductal Adenocarcinoma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Ductal Adenocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Alligator Bioscience, Cardiff Oncology, Novartis, and others.

Ocular Hypertension Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, and others.

DelveInsight’s, “Ocular Hypertension Pipeline Insight 2023” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ocular Hypertension pipeline landscape. It covers the Ocular Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ocular Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ocular Hypertension Pipeline Report

DelveInsight’s Ocular Hypertension pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ocular Hypertension treatment.
The leading Ocular Hypertension Companies include Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others.
Promising Ocular Hypertension Pipeline Therapies include NCX-470, QLS-101, TO-O-1001, and others.
December 2023: AbbVie announced a study of Phase 1 & 2 clinical trials for AGN-193408 SR and Lumigan. This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension.
November 2023: Nicox Ophthalmics Inc. announced a study of Phase 3 clinical trials for NCX 470 0.1% and Latanoprost 0.005%. The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

Request a sample and discover the recent advances in Ocular Hypertension Treatment Drugs @ Ocular Hypertension Pipeline Report

The Ocular Hypertension pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ocular Hypertension drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ocular Hypertension clinical trial landscape.

Ocular Hypertension Overview

Ocular hypertension occurs when the pressure inside the eye exceeds the range considered normal and goes higher than 21 mm Hg. The increase in intraocular pressure (progressive with age, although may also be due to other disorders or causes) is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease.

Find out more about Ocular Hypertension Treatment Landscape @ Drugs for Ocular Hypertension Treatment

Ocular Hypertension Emerging Drugs Profile

NCX-470: Nicox
QLS-101: Qlaris Bio
TO-O-1001: TheratOcular Biotek Co., Ltd.

Ocular Hypertension Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Ocular Hypertension. The Ocular Hypertension companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

DelveInsight’s Ocular Hypertension pipeline report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Ocular Hypertension Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Learn more about the emerging Ocular Hypertension Pipeline Therapies @ Ocular Hypertension Clinical Trials Assessment

Scope of the Ocular Hypertension Pipeline Report

Coverage- Global
Ocular Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Ocular Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Ocular Hypertension Companies- Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others.
Ocular Hypertension Pipeline Therapies- NCX-470, QLS-101, TO-O-1001, and others.

Dive deep into rich insights for new drugs for Ocular Hypertension treatment, Visit @ Ocular Hypertension Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Ocular Hypertension: Overview
Pipeline Therapeutics
Therapeutic Assessment
Ocular Hypertension– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
NCX-470: Nicox
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
QLS-101: Qlaris Bio
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
TO-O-1001: TheratOcular Biotek Co., Ltd.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Ocular Hypertension Key Companies
Ocular Hypertension Key Products
Ocular Hypertension- Unmet Needs
Ocular Hypertension- Market Drivers and Barriers
Ocular Hypertension- Future Perspectives and Conclusion
Ocular Hypertension Analyst Views
Ocular Hypertension Key Companies
Appendix

For further information on the Ocular Hypertension Pipeline Therapeutics, reach out @ Ocular Hypertension Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ocular Hypertension Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, and others.

Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen

DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Osteoarthritis Pipeline Report

DelveInsight’s Osteoarthritis pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis treatment.
The leading companies working in the Osteoarthritis Market include Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
Promising Osteoarthritis Pipeline Therapies in the various stages of development include Hyaluronic Acid, V120083, Naproxen, EP-104IAR, Hyalgan, and others.
October 2023: Regeneron Pharmaceuticals announced a study of Phase 3 clinical trials for Fasinumab. The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
October 2023: Biosplice Therapeutics Inc. announced a study of Phase 3 clinical trials for Lorecivivint. This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize standard outcomes to evaluate the safety and efficacy of lorecivivint.

Request a sample and discover the recent advances in Osteoarthritis Treatment Drugs @ Osteoarthritis Pipeline Report

In the Osteoarthritis pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, Osteoarthritis clinical trials, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Osteoarthritis Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected.

Find out more about Osteoarthritis Therapeutics Assessment @ Osteoarthritis Preclinical and Discovery Stage Products

Osteoarthritis Emerging Drugs Profile

Lorecivivint: Biosplice Therapeutics
CYP 004: Cynata Therapeutics
JTA-004: Bone Therapeutics
SMUP-IA-01: Medipost
TTAX03: Tissue Tech

Osteoarthritis Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.

DelveInsight’s Osteoarthritis pipeline report covers around 130+ products under different phases of Osteoarthritis clinical trials development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous

Osteoarthritis Pipeline Products have been categorized under various Molecule types such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Learn more about the emerging Osteoarthritis Pipeline Therapies @ Osteoarthritis Clinical Trials Assessment

Scope of the Osteoarthritis Pipeline Report

Coverage- Global
Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
Osteoarthritis Pipeline Therapies- Hyaluronic Acid, V120083, Naproxen, EP-104IAR, Hyalgan, and others.

Dive deep into rich insights for new drugs for Osteoarthritis Treatment, Visit @ Osteoarthritis Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Osteoarthritis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Osteoarthritis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Lorecivivint: Biosplice Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TTAX03: Tissue Tech
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
GLPG-0555: Gilead Sciences
Drug profiles in the detailed report…..
Preclinical Stage Products
Protego-PD: Plakous Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Osteoarthritis Key Companies
Osteoarthritis Key Products
Osteoarthritis- Unmet Needs
Osteoarthritis- Market Drivers and Barriers
Osteoarthritis- Future Perspectives and Conclusion
Osteoarthritis Analyst Views
Osteoarthritis Key Companies
Appendix

For further information on the Osteoarthritis Pipeline therapeutics, reach out to Osteoarthritis Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen

Prostate Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics

DelveInsight’s, “Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Prostate Cancer Pipeline Report

DelveInsight’s Prostate Cancer pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Prostate Cancer treatment.
The leading companies working in the Prostate Cancer Market include Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
Promising Prostate Cancer Pipeline Therapies in the various stages of development include Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.
December 2023: Amunix, a Sanofi Company announced a study of Phase 1 & 2 clinical trials for AMX-500 (SAR446329). The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expansion (Part 2).
November 2023: AstraZeneca announced a study of Phase 3 clinical trials for abiraterone acetate. The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
April 2023: Surface Oncology announced a study of phase 2 clinical trails for SRF617, etrumadenant, and zimberelimab. This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
August 2023: AstraZeneca announced a study of phase 3 clinical trials for olaparib and abiraterone acetate. The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

Request a sample and discover the recent advances in Prostate Cancer Treatment Drugs @ Prostate Cancer Infection Pipeline Outlook Report

In the Prostate Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Prostate Cancer Overview

The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate Cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S.

Find out more about Prostate Cancer Treatment Landscape @ Drugs for Prostate Cancer Treatment

Prostate Cancer Emerging Drugs Profile

Pembrolizumab: Merck & Co
Talazoparib: Pfizer
ODM-208: Orion
ZEN 3694: Zenith Epigenetics
EPI-7386: ESSA Pharma

Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the Prostate Cancer therapies. The Prostate Cancer companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

DelveInsight’s Prostate Cancer pipeline report covers around 200+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Prostate Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Learn more about the emerging Prostate Cancer Pipeline Therapies @ Prostate Cancer Clinical Trials Assessment

Scope of the Prostate Cancer Pipeline Report

Coverage- Global
Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
Prostate Cancer Pipeline Therapies- Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.

Dive deep into rich insights for new drugs for Prostate Cancer treatment, Visit @ Prostate Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Prostate Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Pembrolizumab: Merck & Co
Drug profiles in the detailed report….
Mid Stage Products (Phase II)
ODM-208: Orion Pharma
Drug profiles in the detailed report….
Early Stage Products (Phase I)
EPI 7386: ESSA Pharma
Drug profiles in the detailed report….
Preclinical and Discovery Products
Drug name: Company name
Drug profiles in the detailed report…
Inactive Products
Prostate Cancer Key Companies
Prostate Cancer Key Products
Prostate Cancer- Unmet Needs
Prostate Cancer- Market Drivers and Barriers
Prostate Cancer- Future Perspectives and Conclusion
Prostate Cancer Analyst Views
Prostate Cancer Key Companies
Appendix

For further information on the Prostate Cancer pipeline therapeutics, reach out to Prostate Cancer Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics

Rheumatoid Arthritis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences

DelveInsight’s, “Rheumatoid Arthritis Pipeline Insight 2023” report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in the Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Rheumatoid Arthritis Pipeline Report

DelveInsight’s Rheumatoid Arthritis pipeline report depicts a robust space with 95+ active players working to develop 100+ pipeline therapies for Rheumatoid Arthritis treatment.
The leading companies working in the Rheumatoid Arthritis Market include Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc. PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences Inc., ICMBIO, and others.
Promising Rheumatoid Arthritis Pipeline Therapies in the various stages of development etanercept, M2951, Adalimumab, methotrexate, ENBREL®, Enbrel, Certolizumab pegol, LY3871801, and others.
November 2023: SynAct Pharma Aps announced a study of Phase 2 clinical trials for 100 mg AP1189. The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate (MTX).
October 2023: Eli Lilly and Company announced a study of Phase 2 clinical trials for LY3871801. The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
August 2023: Eli Lilly and Company announced a study of phase 4 clinical trials for Baricitinib and TNF Inhibitor. This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors concerning venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
August 2023: Teijin America Inc. announced a study of phase 1 clinical trials for TCK-276. The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).

Request a sample and discover the recent advances in Rheumatoid Arthritis Treatment Drugs @ Rheumatoid Arthritis Pipeline Outlook Report

In the Rheumatoid Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease known to adversely impact the joints of the body. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body; on the onset of disease, the immune response primarily attacks and harms the joints.

Find out more about Rheumatoid Arthritis Treatment Landscape @ Drugs for Rheumatoid Arthritis Treatment

Rheumatoid Arthritis Emerging Drugs Profile

SM03: SinoMab
SHR0302: Jiangsu Hengrui Medicine
RC18: RemeGen
Zalunfiban: CeleCor Therapeutics
ABBV-3373: Abbvie
Dazodalibep: Horizon Therapeutics
AP1189: Synact Pharma
Dekavil: Philogen

Rheumatoid Arthritis Pipeline Therapeutics Assessment

There are approx. 95+ key companies which are developing the Rheumatoid Arthritis therapies. The Rheumatoid Arthritis companies which have their Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. Phase I/II include, RHEACELL.

DelveInsight’s Rheumatoid Arthritis pipeline report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Rheumatoid Arthritis Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Learn more about the emerging Rheumatoid Arthritis Pipeline Therapies @ Rheumatoid Arthritis Clinical Trials Assessment

Scope of the Rheumatoid Arthritis Pipeline Report

Coverage- Global
Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Rheumatoid Arthritis Companies- Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc. PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences Inc., ICMBIO, and others.
Rheumatoid Arthritis Pipeline Therapies- etanercept, M2951, Adalimumab, methotrexate, ENBREL®, Enbrel, Certolizumab pegol, LY3871801, and others.

Dive deep into rich insights for new drugs for Rheumatoid Arthritis treatment, Visit @ Rheumatoid Arthritis Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Rheumatoid Arthritis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Rheumatoid Arthritis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
SM03: SinoMab
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABBV-3373: Abbvie
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SVT 6A4710: Servatus Biopharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SYN060: Synermore Biologics Co., Ltd.
Drug profiles in the detailed report…..
Preclinical Stage Products
CABA-201: Cabaletta Bio
Drug profiles in the detailed report…..
Inactive Products
Rheumatoid Arthritis Collaborations Assessment- Licensing / Partnering / Funding
Rheumatoid Arthritis Unmet Needs
Rheumatoid Arthritis Market Drivers and Barriers
Appendix

For further information on the Rheumatoid Arthritis pipeline therapeutics, reach out to Rheumatoid Arthritis Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences

Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others

DelveInsight’s, “Exosomes Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 110+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Exosomes Pipeline Report

DelveInsight’s Exosomes pipeline report depicts a robust space with 60+ active players working to develop 110+ pipeline therapies for Exosomes treatment.
The leading companies working in the Exosomes Market include Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
Promising Exosomes Pipeline Therapies in the various stages of development include Exosome ointment, EV-Pure™, Zofin, Olmutinib, and others.
December 2023: Direct Biologics LLC announced a study of Phase 3 clinical trials for ExoFlo. To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
November 2023: Organicell Regenerative Medicine announced a study of Phase 1 & 2 clinical trials for Zofin. The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
October 2023: Vitti Labs LLC announced a study of Phase 1 clinical trials for EV-Pure™. The VL-POI-01 study is designed to evaluate the safety and efficacy of human placental mesenchymal stem cell derived exosome treatment in patients with premature ovarian insufficiency (POI) and diminished ovarian reserve.

Request a sample and discover the recent advances in Exosomes Treatment Drugs @ Exosomes Pipeline Outlook Report

In the Exosomes pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Exosomes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Exosomes Overview

An exosome is a type of extracellular vesicle (EV), a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages released by most cells. Exosomes are released from cells upon fusion of an intermediate endocytic compartment, the multivesicular body (MVB), with the plasma membrane. This liberates intraluminal vesicles (ILVs) into the extracellular milieu and the vesicles thereby released are what we know as exosomes.

Find out more about Exosomes Treatment Landscape @ Drugs for Exosomes Treatment

Exosomes Emerging Drugs Profile

CAP-1002: Capricor
Progenza: Regeneus
AGLE 102: Aegle Therapeutics
Zofin: Organicell Regenerative Medicine
Exo-101: Exogenus Therapeutics
COYA 201: Coya Therapeutics

Exosomes Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for Exosomes. The Exosomes Companies which have their Exosomes drug candidates in the most advanced stage, i.e. phase III include, Capricor.

DelveInsight’s Exosomes pipeline report covers around 110+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Exosomes Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Learn more about the emerging Exosomes Pipeline Therapies @ Exosomes Clinical Trials Assessment

Scope of the Exosomes Pipeline Report

Coverage- Global
Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Exosomes Companies- Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
Exosomes Pipeline Therapies- Exosome ointment, EV-Pure™, Zofin, Olmutinib, and others.

Dive deep into rich insights for new drugs for Exosomes Treatment, Visit @ Exosomes Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Exosomes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Exosomes– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
CAP-1002: Capricor
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Progenza: Regeneus
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
StemXO Endosome Therapy: Stem XO Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Exo-101: Exogenus Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Exosome – Collaborations Assessment- Licensing / Partnering / Funding
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Appendix

For further information on the Exosomes pipeline therapeutics, reach out @ Exosomes Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others